LBPS — 4D PHARMA ADR REP 8 ORD share price
Last Trade - 00:00- $222.06m
- $211.34m
- $0.53m
Momentum
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | |||
| EPS Growth (f) | |||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | |||
| Price to Tang. Book | |||
| Price to Free Cashflow | |||
| Price to Sales | |||
| EV to EBITDA | |||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | |||
| Return on Equity | |||
| Operating Margin | |||
Financial Summary
| Year End 31st Dec | Unit | 2016 | 2017 | 2018 | 2019 | 2020 | 2021E | 2022E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | n/a | 0.21 | 0.53 | n/a | 16.2 | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Health trend(F-Score)
Bankruptcy Score(Z-Score)
Earnings Manipulation Risk(M-Score)
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Latest News for LBPS
Similar to LBPS
4D PHARMA ADR REP 8 ORD
NASDAQ Global Market
89BIO ORD
NASDAQ Global Market
ACCELERON PHARMA ORD
NASDAQ Global Market
ACELRX PHARMACEUTICALS ORD
NASDAQ Global Market
ADAGENE 4 ADR REP 5 ORD
NASDAQ Global Market
ADMA BIOLOGICS ORD
NASDAQ Global Market
ADVERUM BIOTECHNOLOGIES ORD
NASDAQ Global Market
AEGLEA BIOTHERAPEUTICS ORD
NASDAQ Global Market
AERIE PHARMACEUTICALS ORD
NASDAQ Global Market
AFFIMED ORD
NASDAQ Global Market
AKEBIA THERAPEUTICS ORD
NASDAQ Global Market
ALPINE IMMUNE SCIENCES ORD
NASDAQ Global Market
ALTIMMUNE ORD
NASDAQ Global Market
AMARIN ADR REP 1 ORD
NASDAQ Global Market
APPLIED GENETIC TECHNOLOGIES ORD
NASDAQ Global Market
APPLIED THERAPEUTICS ORD
NASDAQ Global Market
ARDELYX ORD
NASDAQ Global Market
ASLAN PHARMACEUTICALS ADR REP 5 ORD
NASDAQ Global Market
AURINIA PHARMACEUTICALS ORD
NASDAQ Global Market
AXCELLA HEALTH ORD
NASDAQ Global Market
FAQ
As of Today at 16:51 UTC, shares in 4D PHARMA ADR REP 8 ORD are trading at $9.70, giving the company a market capitalisation of $222.06m. This share price information is delayed by 15 minutes.
Shares in 4D PHARMA ADR REP 8 ORD are currently trading at $9.70 and the price has moved by over the past 365 days. In terms of relative price strength the 4D PHARMA ADR REP 8 ORD share price has matched the S&P500 Index by over the past year.
The overall consensus recommendation for 4D PHARMA ADR REP 8 ORD is Buy. You can view the full broker recommendation list by unlocking its StockReport.
4D PHARMA ADR REP 8 ORD does not currently pay a dividend.
4D PHARMA ADR REP 8 ORD does not currently pay a dividend.
4D PHARMA ADR REP 8 ORD does not currently pay a dividend.
To buy shares in 4D PHARMA ADR REP 8 ORD you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
Shares in 4D PHARMA ADR REP 8 ORD are currently trading at $9.70, giving the company a market capitalisation of $222.06m.
Here are the trading details for 4D PHARMA ADR REP 8 ORD:
- Country of listing: United States
- Exchange: NMQ
- Ticker Symbol: LBPS
Based on an overall assessment of its quality, value and momentum 4D PHARMA ADR REP 8 ORD is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in 4D PHARMA ADR REP 8 ORD is $5.63. That is 41.96% below the current share price of $9.70.
Analysts covering 4D PHARMA ADR REP 8 ORD currently have a consensus Earnings Per Share (EPS) forecast of -$0.14 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Relative Strength is an often used as a momentum indicator. Price trends tend to persist, so it's worth looking at them when it comes to a share like 4D PHARMA ADR REP 8 ORD. Over the past six months, its share price has matched the S&P500 Index by .
At the current price of $9.70, shares in 4D PHARMA ADR REP 8 ORD are trading -13.81% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
We are not able to find PE ratio data for 4D PHARMA ADR REP 8 ORD.
We do not have data on 4D PHARMA ADR REP 8 ORD's directors
We do not have data on 4D PHARMA ADR REP 8 ORD's shareholders